**Model-Adjusted Proportion of Participants with Weight Change ≥10% by Sex and Race**

|  | Doravirine Group | | Darunavir Group | | Efavirenz Group | |
| --- | --- | --- | --- | --- | --- | --- |
|  | n | Estimated Proportion (%) | n | Estimated Proportion (%) | n | Estimated Proportion (%) |
| **Week 48** | | | | | | |
| Male | 636 | 7.5 | 272 | 5.8 | 353 | 4.9 |
| Female | 114 | 15.4 | 42 | 10.2 | 49 | 13.8 |
| Black | 136 | 16.1 | 63 | 6.6 | 66 | 6.8 |
| Non-Black | 614 | 6.9 | 251 | 6.4 | 336 | 6.0 |
| **Week 96** | | | | | | |
| Male | 574 | 14.2 | 234 | 16.7 | 316 | 11.8 |
| Female | 102 | 25.6 | 32 | 18.5 | 46 | 20.1 |
| Black | 113 | 25.3 | 52 | 15.4 | 53 | 13.5 |
| Non-Black | 563 | 13.8 | 214 | 17.3 | 309 | 12.8 |
| n= Number of subjects included in the analysis. Subjects with missing variables are excluded from the analysis. Weight change percent is 100\*(weight change from baseline)/(baseline weight). Proportions of change ≥10%, risk difference and p-value are estimated from a generalized linear model with binomial distribution, identity link and the variables for treatment group, region, gender, indicator for black/non-black, interaction terms of treatment by gender and by black indicator, as well as baseline values of age, weight, BMI, log10 CD4 counts and log10 of viral load. | | | | | | |